Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Gliomas, especially IDH-wildtype astrocytomas, are aggressive with limited therapeutic options.
• PTPN7, a tyrosine phosphatase in MAPK signaling, is underexplored in glioma.
• Identifying novel prognostic biomarkers and therapeutic targets is crucial for improving glioma patient survival.

Purpose of the Study:

• To investigate the prognostic significance of PTPN7 in gliomas.
• To analyze the spatial distribution and immune-related functions of PTPN7.
• To evaluate PTPN7 as a potential therapeutic target in glioma treatment.

Main Methods:

• Analysis of PTPN7 mRNA expression using TCGA, CGGA, and single-cell RNA sequencing datasets.
• Prognostic significance assessed via Kaplan-Meier and Cox survival analyses.
• Pathway and immune cell enrichment analysis using Gene Set Enrichment Analysis (GSEA) and CIBERSORT; spatial distribution mapped with spatial transcriptomics and validated by immunohistochemistry.

Main Results:

• PTPN7 is overexpressed in gliomas, particularly IDH-wildtype astrocytomas, correlating with higher tumor grade and poorer survival.
• High PTPN7 expression is linked to T-cell differentiation, myeloid cell activation, and immune cell infiltration.
• Spatial transcriptomics and immunohistochemistry confirm PTPN7 enrichment in tumor regions associated with immune interactions.

Conclusions:

• PTPN7 serves as a prognostic biomarker and immune modulator in gliomas, especially IDH-wildtype astrocytomas.
• PTPN7 expression correlates with tumor aggressiveness and immune infiltration, potentially driving glioma progression.
• Targeting PTPN7 presents a promising therapeutic strategy to enhance immunotherapy efficacy and promote tumor eradication.